NO933126L - Löselige ligander for CD40 - Google Patents
Löselige ligander for CD40Info
- Publication number
- NO933126L NO933126L NO933126A NO933126A NO933126L NO 933126 L NO933126 L NO 933126L NO 933126 A NO933126 A NO 933126A NO 933126 A NO933126 A NO 933126A NO 933126 L NO933126 L NO 933126L
- Authority
- NO
- Norway
- Prior art keywords
- soluble ligands
- soluble
- ligands
- promoting
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/940,605 US5540926A (en) | 1992-09-04 | 1992-09-04 | Soluble and its use in B cell stimulation |
Publications (3)
Publication Number | Publication Date |
---|---|
NO933126D0 NO933126D0 (no) | 1993-09-02 |
NO933126L true NO933126L (no) | 1994-03-07 |
NO311808B1 NO311808B1 (no) | 2002-01-28 |
Family
ID=25475138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19933126A NO311808B1 (no) | 1992-09-04 | 1993-09-02 | Löselige ligander for CD40 |
Country Status (17)
Country | Link |
---|---|
US (2) | US5540926A (no) |
EP (1) | EP0585943B1 (no) |
JP (1) | JP3529815B2 (no) |
KR (1) | KR100319126B1 (no) |
AT (1) | ATE163195T1 (no) |
AU (1) | AU677788B2 (no) |
CA (1) | CA2105552C (no) |
DE (1) | DE69316948T2 (no) |
DK (1) | DK0585943T3 (no) |
ES (1) | ES2113980T3 (no) |
FI (1) | FI113969B (no) |
GR (1) | GR3026100T3 (no) |
HU (1) | HU215949B (no) |
IL (1) | IL106896A (no) |
NO (1) | NO311808B1 (no) |
NZ (1) | NZ248569A (no) |
ZA (1) | ZA936491B (no) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
CA2121798C (en) * | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
US7405270B2 (en) * | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
NZ262576A (en) * | 1993-01-22 | 1999-09-29 | Immunex Corp | Detection and treatment of mutations in a cd-40 ligand gene |
WO1995006481A1 (en) | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
US5874085A (en) * | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
AU1059095A (en) * | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
CA2179196A1 (en) * | 1993-12-23 | 1995-06-29 | Richard J. Armitage | Method of preventing or treating disease characterized by neoplastic cells expressing cd40 |
US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
US5817516A (en) | 1994-04-28 | 1998-10-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods for proliferating and differentiating B cells with high density membrane CD40 ligand |
GB9425060D0 (en) * | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US5645837A (en) * | 1995-01-17 | 1997-07-08 | Thomas Jefferson University | Peptides that inhibit T cell activation and methods of using the same |
AU2556195A (en) | 1995-03-13 | 1996-10-02 | Regents Of The University Of Michigan, The | CD40 binding compositions and methods of using same |
IL122174A (en) * | 1995-06-07 | 2004-07-25 | Immunex Corp | DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA |
DK0833847T3 (da) * | 1995-06-22 | 2003-12-29 | Biogen Inc | Krystaller af fregmenter af CD40-ligand og deres anvendelse |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
WO1997022256A1 (en) * | 1995-12-19 | 1997-06-26 | National Jewish Center For Immunology And Respiratory Medicine | Method to regulate cd40 signaling |
US6451995B1 (en) * | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
IL127912A0 (en) * | 1996-07-10 | 1999-11-30 | Immunex Corp | Method of activating dendritic cells |
US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
JP2001508450A (ja) * | 1997-01-10 | 2001-06-26 | バイオジェン インコーポレイテッド | 抗cd40l化合物の治療学的投与の方法 |
CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
US20050031611A1 (en) * | 1998-05-08 | 2005-02-10 | Beth Israel Deaconess Medical Center | Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis |
JP3581660B2 (ja) | 1999-04-30 | 2004-10-27 | ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー | 潜伏ウイルスの再活性化を予防しウイルスの複製を制御するための方法 |
EP1642596A3 (en) * | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
HUP0202238A3 (en) * | 1999-07-12 | 2004-05-28 | Idec Pharmaceuticals Inc San D | Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
AU6934600A (en) * | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
EP1246643A4 (en) | 1999-10-14 | 2005-05-11 | Jeffery A Ledbetter | DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN |
US20030077263A1 (en) * | 1999-10-29 | 2003-04-24 | Immunex Corporation | Method of activating dendritic cells |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001040275A2 (en) * | 1999-12-06 | 2001-06-07 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptides that stabilize protein antigens and enhance presentation to cd8+ t cells |
US20110041190A1 (en) * | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
ES2267593T3 (es) * | 2000-02-16 | 2007-03-16 | Genentech, Inc. | Anticuerpos anti-april y celulas hibridomas. |
AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
CN1592645A (zh) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
US7786257B2 (en) * | 2000-12-18 | 2010-08-31 | University Of Kansas | Signal-1/signal-2 bifunctional peptide inhibitors |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
KR20040019105A (ko) * | 2001-08-03 | 2004-03-04 | 제넨테크, 인크. | TACIs 및 BR3 폴리펩티드 및 이의 용도 |
US20030211075A1 (en) * | 2001-09-27 | 2003-11-13 | Thorpe Philip E. | Combined compositions for tumor vasculature coagulation and treatment |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
EP1551877A4 (en) * | 2002-07-25 | 2006-01-18 | Genentech Inc | TACI ANTIBODIES AND THEIR USE |
KR101348472B1 (ko) * | 2002-10-17 | 2014-01-07 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
JP2007524591A (ja) * | 2003-03-19 | 2007-08-30 | アイソジェニス・インコーポレイテッド | 同種拒絶反応の特異的阻害 |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
KR20060027801A (ko) * | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | B 세포 장애에 대한 조합 요법 |
US7850962B2 (en) * | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US20090053249A1 (en) * | 2004-07-20 | 2009-02-26 | Yan Qi | Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens |
US8647625B2 (en) | 2004-07-26 | 2014-02-11 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
EP1835027B1 (en) * | 2004-12-07 | 2015-02-25 | Toray Industries, Inc. | Novel cancer antigen peptide and the use thereof |
EP2312315A1 (en) | 2005-05-18 | 2011-04-20 | Novartis AG | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
WO2006128103A2 (en) * | 2005-05-26 | 2006-11-30 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
JP6088723B2 (ja) * | 2005-11-23 | 2017-03-01 | ジェネンテック, インコーポレイテッド | B細胞アッセイに関する組成物及び方法。 |
CA3156538C (en) | 2007-11-01 | 2023-12-12 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
CA2713981C (en) * | 2008-02-08 | 2016-11-01 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
AU2009274502A1 (en) * | 2008-07-25 | 2010-01-28 | Theraclone Sciences, Inc. | Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ARA) |
AU2009276717A1 (en) * | 2008-07-28 | 2010-02-04 | Emergent Product Development Seattle, Llc | Multi-specific binding proteins targeting B cell disorders |
WO2010033722A2 (en) | 2008-09-17 | 2010-03-25 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
AU2010301042B2 (en) | 2009-10-01 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
US9388230B2 (en) | 2010-09-28 | 2016-07-12 | Kahr Medical(2005) Ltd | Compositions and methods for treatment of hematological malignancies |
AU2013225721B2 (en) | 2012-03-02 | 2018-06-14 | The Regents Of The University Of California | Expansion of alloantigen-reactive regulatory T cells |
EP2956165B1 (en) | 2013-02-14 | 2019-09-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
CA2914595C (en) * | 2014-05-19 | 2022-12-13 | F. Hoffmann-La Roche Ag | Method for producing antibodies using ovine b-cells and uses thereof |
EP3370733B1 (en) | 2015-11-02 | 2021-07-14 | Board of Regents, The University of Texas System | Methods of cd40 activation and immune checkpoint blockade |
AU2020345943A1 (en) | 2019-09-10 | 2022-03-31 | Obsidian Therapeutics, Inc. | CA2-IL15 fusion proteins for tunable regulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008114A1 (en) * | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
WO1990012877A1 (en) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
US5227167A (en) * | 1991-06-11 | 1993-07-13 | Alza Corporation | Long-term delivery device including hydrophobic loading dose |
CA2121798C (en) * | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
CA2089229C (en) * | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
WO1994004570A1 (en) * | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
JP4242447B2 (ja) * | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Cd40リガンド遺伝子の突然変異の検出および治療 |
-
1992
- 1992-09-04 US US07/940,605 patent/US5540926A/en not_active Expired - Lifetime
-
1993
- 1993-09-02 NZ NZ248569A patent/NZ248569A/en not_active IP Right Cessation
- 1993-09-02 NO NO19933126A patent/NO311808B1/no not_active IP Right Cessation
- 1993-09-02 ZA ZA936491A patent/ZA936491B/xx unknown
- 1993-09-03 IL IL10689693A patent/IL106896A/xx not_active IP Right Cessation
- 1993-09-03 AT AT93114153T patent/ATE163195T1/de active
- 1993-09-03 FI FI933862A patent/FI113969B/fi not_active IP Right Cessation
- 1993-09-03 DK DK93114153T patent/DK0585943T3/da active
- 1993-09-03 HU HU9302484A patent/HU215949B/hu unknown
- 1993-09-03 KR KR1019930017670A patent/KR100319126B1/ko not_active IP Right Cessation
- 1993-09-03 EP EP93114153A patent/EP0585943B1/en not_active Expired - Lifetime
- 1993-09-03 DE DE69316948T patent/DE69316948T2/de not_active Expired - Lifetime
- 1993-09-03 CA CA002105552A patent/CA2105552C/en not_active Expired - Lifetime
- 1993-09-03 AU AU46120/93A patent/AU677788B2/en not_active Expired
- 1993-09-03 ES ES93114153T patent/ES2113980T3/es not_active Expired - Lifetime
- 1993-09-06 JP JP24358193A patent/JP3529815B2/ja not_active Expired - Lifetime
-
1996
- 1996-07-30 US US08/690,096 patent/US5945513A/en not_active Expired - Lifetime
-
1998
- 1998-02-12 GR GR980400208T patent/GR3026100T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
FI933862A (fi) | 1994-03-05 |
FI933862A0 (fi) | 1993-09-03 |
GR3026100T3 (en) | 1998-05-29 |
EP0585943A3 (en) | 1994-07-06 |
KR940007179A (ko) | 1994-04-26 |
HUT69977A (en) | 1995-09-28 |
AU677788B2 (en) | 1997-05-08 |
HU9302484D0 (en) | 1993-11-29 |
NO311808B1 (no) | 2002-01-28 |
NO933126D0 (no) | 1993-09-02 |
JP3529815B2 (ja) | 2004-05-24 |
HU215949B (hu) | 1999-03-29 |
IL106896A (en) | 2005-12-18 |
CA2105552A1 (en) | 1994-03-05 |
FI113969B (fi) | 2004-07-15 |
KR100319126B1 (ko) | 2002-05-13 |
US5540926A (en) | 1996-07-30 |
EP0585943A2 (en) | 1994-03-09 |
ZA936491B (en) | 1994-03-25 |
NZ248569A (en) | 1995-10-26 |
CA2105552C (en) | 2009-08-18 |
DE69316948D1 (de) | 1998-03-19 |
AU4612093A (en) | 1994-03-10 |
DK0585943T3 (da) | 1998-09-23 |
JPH06315383A (ja) | 1994-11-15 |
DE69316948T2 (de) | 1998-10-01 |
ES2113980T3 (es) | 1998-05-16 |
EP0585943B1 (en) | 1998-02-11 |
US5945513A (en) | 1999-08-31 |
ATE163195T1 (de) | 1998-02-15 |
IL106896A0 (en) | 1993-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0585943T3 (da) | Opløselige ligander for CD40 | |
DE3779346D1 (de) | Zusammensetzung zur behandlung der haut. | |
DE69703649D1 (de) | Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies | |
BE2012C001I2 (no) | ||
DE69534130D1 (de) | Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen. | |
BG95935A (bg) | Метод и средство за приемане на дексмедетомидин директно през кожата | |
NO923953D0 (no) | Peptider | |
MX9700538A (es) | Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares. | |
TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
ATE222769T1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
DE58905201D1 (de) | Mittel zur behandlung des parkinson-syndroms. | |
DE3782214D1 (de) | Mittel zur behandlung des scheidenmilieus. | |
FR2491334B1 (no) | ||
ATE347372T1 (de) | Vakzine zur behandlung von mycosen | |
DE58906239D1 (de) | Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn. | |
EP0325129A3 (en) | Disubstituted pyridines | |
DE68903208D1 (de) | Verfahren zur thermischen behandlung von laktoferrin. | |
EP0647138A4 (en) | POLYPEPTIDES AVAILABLE FROM FASCIOLA SPECIES, AND VACCINE, THERAPY PROCEDURES AND DNA SEQUENCES ENCODING THESE PEPTIDES. | |
DE69408394D1 (de) | 4-Piperidino-piperidin zur Behandlung von Tumoren | |
DE69000960D1 (de) | Zusammensetzung zur behandlung von pigmentierung. | |
DE68908445D1 (de) | Mittel zur behandlung von lebererkrankungen. | |
FI971879A0 (fi) | Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi | |
DE69002821D1 (de) | Zusammensetzung zur haarbehandlung. | |
DE68914886D1 (de) | Mittel zur Behandlung von Raynaud's Krankheit. | |
ITTO920049A1 (it) | Apparecchio e metodo per il trattamento di tessuti, in particolare tessuti adiposi. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |